Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro

Veterinary Pathology

Volumn 47, Issue 2, 2010, Pages 358-367

  Csizmadia, V ^a   Csizmadia, E ^a   Silverman, L ^a   Simpson, C ^a   Raczynski, A ^a   O'Brien, L ^a   Gallacher, M ^a   Cardoza, K ^a   Kadambi, V J ^a   Fedyk, E R ^a   Alden, C L ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Aggresome; BALB c mice; PC12 neuronal cell; Peripheral neuropathy; Proteasome

Indexed keywords

ACETYLCYSTEINE; BORONIC ACID DERIVATIVE; BORTEZOMIB; DRUG DERIVATIVE; EPOXOMICIN; LACTACYSTIN; OLIGOPEPTIDE; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; UBIQUITIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL STRAIN; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; IC 50; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; PERIPHERAL NEUROPATHY; RAT; WESTERN BLOTTING;

ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PC12 CELLS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; UBIQUITIN;

ANIMALIA; MUS;

EID: 77954023420     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985809358423     Document Type: Article

References (32)

1. Adams J., Kauffman M.: Development of the proteasome inhibitor VELCADE® (Bortezomib). Cancer Invest 22:304-311, 2004.
2. Argyriou AA, Iconomou G., Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593-1599, 2008.
3. Arispe N., Pollard HB, Rojas E.: Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1- 40)] in bilayer membranes. Proc Natl Acad Sci U S A 90:10573- 10577, 1993.
4. Bennett EJ, Bence NF, Jayakumar R., Kopito RR: Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17:351-365, 2005.
5. Bossy-Wetzel E., Schwarzenbacher R., Lipton SA: Molecular pathways to neurodegeneration. Nat Med 10:S2-S9, 2004.
6. Bross PF, Kane R., Farrell AT, Abraham S., Benson K., Brower ME, Bradley S., Gobburu JV, Goheer A., Lee SL, Leighton J., Liang CY, Lostritto RT, McGuinn WD, Morse DE, Rahman A., Rosario LA, Verbois SL, Williams G., Wang YC, Pazdur R.: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10:3954-64, 2004.
7. Carrell RW: Cell toxicity and conformational disease. Trends Cell Biol 15:574-580, 2005.
8. Csizmadia V., Raczynski A., Csizmadia E., Fedyk ER, Rottman J., Alden CL: Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. Neurotoxicology 29:232-243, 2008.
9. Ding WX, Ni HM, Gao W., Yoshimori T., Stolz DB, Ron D., Yin XM: Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171:513-524, 2007.
10. Ding WX, Yin XM: Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 4:141-150, 2008.
11. Fornai F., Lenzi P., Lazzeri G., Ferrucci M., Fulceri F., Giorgi FS, Falleni A., Ruggieri S., Paparelli A.: Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity. Brain Res 1129:174-190, 2007.
12. Gunawardena S., Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B., Sintasath L., Bonini NM, Goldstein LS: Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40, 2003.
13. Hegde AN, Upadhya SC: The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 30:587-595, 2007.
14. Kim KB, Myung J., Sin N., Crews CM: Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 9:3335-3340, 1999.
15. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K.: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880-884, 2006.
16. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524-530, 2000.
17. Kozlowski L., Stoklosa T., Omura S., Wojcik C., Wojtukiewicz MZ, Worowski K., Ostrowska H.: Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol 22:211-215, 2001.
18. Kyle RA, Rajkumar SV: Multiple myeloma. Blood 111:2962- 2972, 2008.
19. Lightcap ES, McCormack TA, Pien CS, Chau V., Adams J., Elliott PJ: Proteasome inhibition measurements: clinical application. Clin Chem 46:673-683, 2000.
20. Marx FP, Holzmann C., Strauss KM, Li L., Eberhardt O., Gerhardt E., Cookson MR, Hernandez D., Farrer MJ, Kachergus J., Engelender S., Ross CA, Berger K., Schols L., Schulz JB, Riess O., Kruger R.: Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 12:1223-1231, 2003.
21. Orlowski RZ, Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649-1657, 2008.
22. Richardson PG, Sonneveld P., Schuster MW, Stadtmauer EA, Facon T., Harousseau JL, Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., Blade J., Boccadoro M., Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline [published online ahead of print January 16, 2009]. Br J Haematol.
23. Rideout HJ, Larsen KE, Sulzer D., Stefanis L.: Proteasomal inhibition leads to formation of ubiquitin/alpha-synucleinimmunoreactive inclusions in PC12 cells. J Neurochem 78:899- 908, 2001.
24. Ross CA, Poirier MA: Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6:891-898, 2005.
25. Siau C., Xiao W., Bennett GJ: Paclitaxel- and vincristineevoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 201:507-514, 2006.
26. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279, 2003.
27. Silverman L., Csizmadia V., Cardoza K., Gallacher M., Windman M., Murnane M., Csizmadia E., Bissonnette A., Coleman S., Pierce J., Lane J., Kadambi VJ, Alden CL: Model for proteasome inhibition associated peripheral neuropathy [abstract]. Toxicol Pathol 34:989, 2006.
28. Tai HC, Schuman EM: Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 9:826-838, 2008.
29. Trojanowski JQ, Goedert M., Iwatsubo T., Lee VM: Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 5:832-837, 1998.
30. Voorhees PM, Dees EC, O'Neil B., Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003.
31. Winklhofer KF, Tatzelt J., Haass C.: The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27:336-349, 2008.
32. Wu JJ, Huang DB, Pang KR, Hsu S., Tyring SK: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 153:254-273, 2005.